Treatment of metastatic renal cancers
Treatment of metastatic renal cancers
Dátum
Szerzők
Levy, Adam
Folyóirat címe
Folyóirat ISSN
Kötet címe (évfolyam száma)
Kiadó
Absztrakt
Renal cancer represents approximately 3 % of total malignancies. Based on the statistics distant metastasis is present at least 30% of renal cancers at the time of diagnosis. The metastatic renal tumors have an extremely high rate of mortality and poor survival. The conventional chemotherapy was not effective for the treatment of metastatic renal carcinomas. However, in the past decade the administration of different targeted therapies improved the survival of metastatic renal cell carcinomas. At present we use antivascular endothelial growth factor receptor (VEGFR) inhibitor, tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors in the adjuvant setting for metastatic renal tumors. Due to the administration of the targeted therapies the outcome of this population improved, but, despite the partly prolonged survival, the majority of patients will develop resistance to targeted therapies.
Leírás
Kulcsszavak
renal, cancer, treatment